140 Development of first-in-class ERAP2 inhibitors to modulate the cancer immunopeptidome

• Peter Joyce,
• Martin Quibell,
• Jason Shiers,
• Kristopher Clark,
• Nicola Ternette,
• Kate Anderton,
• Wayne Paes,
• Michael Berry,
• Sam Humphrey,
• Ionut Dragomir,
• Joud Sabouni,
• Samantha Garside

Affiliations

Peter Joyce

1Grey Wolf Therapeutics Ltd, Oxford, UK

Martin Quibell

1Grey Wolf Therapeutics Ltd, Oxford, UK

Jason Shiers

2Sygnature Discovery, Nottingham, UK

Kristopher Clark

1Grey Wolf Therapeutics, Oxford, Oxford, UK

Nicola Ternette

6University of Oxford, Oxford, UK

Kate Anderton

2Grey Wolf Therapeutics, Oxford, UK

Wayne Paes

4University of Oxford, Oxford, UK

Michael Berry

specialist trainee year 4, anaesthesia, Watford General Hospital

Sam Humphrey

2Grey Wolf Therapeutics, Milton, Oxford, UK

Ionut Dragomir

2Grey Wolf Therapeutics, Milton, Oxford, UK

Joud Sabouni

5Sygnature Discovery, Nottingham, UK

Samantha Garside

5Sygnature Discovery, Nottingham, UK